El-Dana F - Search Results

1

Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML.

Tyagi A, Ly S, El-Dana F, Yuan B, Jaggupilli A, Grimm S, Konopleva M, Bühring HJ, Battula VL. Tyagi A, et al. Among authors: el dana f. Blood. 2022 May 5;139(18):2782-2796. doi: 10.1182/blood.2021014671. Blood. 2022. PMID: 35231101 Free PMC article.

2

Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway.

Yuan B, El Dana F, Ly S, Yan Y, Ruvolo V, Shpall EJ, Konopleva M, Andreeff M, Battula VL. Yuan B, et al. Among authors: el dana f. PLoS One. 2020 Nov 30;15(11):e0242809. doi: 10.1371/journal.pone.0242809. eCollection 2020. PLoS One. 2020. PMID: 33253299 Free PMC article.

3

[No title available]

[No authors listed] [No authors listed] PMID: 36163810

4

[No title available]

[No authors listed] [No authors listed] PMID: 36163811

5

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2⁺ breast cancer stem-like cells.

Ly S, Anand V, El-Dana F, Nguyen K, Cai Y, Cai S, Piwnica-Worms H, Tripathy D, Sahin AA, Andreeff M, Battula VL. Ly S, et al. Among authors: el dana f. J Immunother Cancer. 2021 Mar;9(3):e001197. doi: 10.1136/jitc-2020-001197. J Immunother Cancer. 2021. PMID: 33722905 Free PMC article.

6

Metabolic stress induces GD2⁺ cancer stem cell-like phenotype in triple-negative breast cancer.

Jaggupilli A, Ly S, Nguyen K, Anand V, Yuan B, El-Dana F, Yan Y, Arvanitis Z, Piyarathna DWB, Putluri N, Piwnica-Worms H, Manning HC, Andreeff M, Battula VL. Jaggupilli A, et al. Among authors: el dana f. Br J Cancer. 2022 Mar;126(4):615-627. doi: 10.1038/s41416-021-01636-y. Epub 2021 Nov 22. Br J Cancer. 2022. PMID: 34811508 Free PMC article.

7

Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge.

El Dana F, Garces Narvaez SA, El-Mallawany NK, Agrusa JE, Dreyer ZE, Marcogliese AN, Elghetany MT, Punia JN, Ok CY, Patel KP, Lopez-Terrada DH, Fisher KE, Curry CV. El Dana F, et al. Pediatr Dev Pathol. 2024 Mar 11:10935266241230600. doi: 10.1177/10935266241230600. Online ahead of print. Pediatr Dev Pathol. 2024. PMID: 38468555 Free article.

8

TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.

Tyagi A, Jaggupilli A, Ly S, Yuan B, El-Dana F, Hegde VL, Anand V, Kumar B, Puppala M, Yin Z, Wong STC, Mollard A, Vankayalapati H, Foulks JM, Warner SL, Daver N, Borthakur G, Battula VL. Tyagi A, et al. Among authors: el dana f. Leukemia. 2024 Jan;38(1):82-95. doi: 10.1038/s41375-023-02086-6. Epub 2023 Nov 25. Leukemia. 2024. PMID: 38007585

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page